Surgeon recommendations and receipt of mastectomy for treatment of breast cancer
- PMID: 19826024
- PMCID: PMC4137962
- DOI: 10.1001/jama.2009.1450
Surgeon recommendations and receipt of mastectomy for treatment of breast cancer
Abstract
Context: There is concern that mastectomy is overused in the United States.
Objectives: To evaluate the association of patient-reported initial recommendations by surgeons and those given when a second opinion was sought with receipt of initial mastectomy; and to assess the use of mastectomy after attempted breast-conserving surgery (BCS).
Design, setting, and patients: A survey of women aged 20 to 79 years with intraductal or stage I and II breast cancer diagnosed between June 2005 and February 2007 and reported to the National Cancer Institute's Surveillance, Epidemiology, and End Results registries for the metropolitan areas of Los Angeles, California, and Detroit, Michigan. Patients were identified using rapid case ascertainment, and Latinas and blacks were oversampled. Of 3133 patients sent surveys, 2290 responded (73.1%). A mailed survey was completed by 96.5% of respondents and 3.5% completed a telephone survey. The final sample included 1984 female patients (502 Latinas, 529 blacks, and 953 non-Hispanic white or other).
Main outcome measures: The rate of initial mastectomy and the perceived reason for its use (surgeon recommendation, patient driven, medical contraindication) and the rate of mastectomy after attempted BCS.
Results: Of the 1984 patients, 1468 had BCS as an initial surgical therapy (75.4%) and 460 had initial mastectomy, including 13.4% following surgeon recommendation and 8.8% based on patient preference. Approximately 20% of patients (n = 378) sought a second opinion; this was more common for those patients advised by their initial surgeon to undergo mastectomy (33.4%) than for those advised to have BCS (15.6%) or for those not receiving a recommendation for one procedure over another (21.2%) (P < .001). Discordance in treatment recommendations between surgeons occurred in 12.1% (n = 43) of second opinions and did not differ on the basis of patient race/ethnicity, education, or geographic site. Among the 1459 women for whom BCS was attempted, additional surgery was required in 37.9% of patients, including 358 with reexcision (26.0%) and 167 with mastectomy (11.9%). Mastectomy was most common in patients with stage II cancer (P < .001).
Conclusion: Breast-conserving surgery was recommended by surgeons and attempted in the majority of patients evaluated, with surgeon recommendation, patient decision, and failure of BCS all contributing to the mastectomy rate.
References
-
- Edwards BK, Brown ML, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975–2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst. 2005;97(19):1407–1427. - PubMed
-
- Locker GY, Sainsbury JR, Cuzick J ATAC Trialists’ Group. Breast surgery in the Arimidex, Tamoxifen Alone or in Combination (ATAC) trial: American women are more likely than women from the United Kingdom to undergo mastectomy. Cancer. 2004;101(4):735–740. - PubMed
-
- Nattinger AB, Gottlieb MS, Hoffman RG, Walker AP, Goodwin JS. Minimal increase in use of breast-conserving surgery from 1986 to 1990. Med Care. 1996;34(5):479–489. - PubMed
-
- Avon Foundation Breast Center at Johns Hopkins. [Accessed September 3, 2009.];Quality corner. http://www.hopkinsbreastcenter.org/about_us/quality.
-
- Cedars-Sinai Medical Center. [Accessed September 3, 2009.];Measuring quality of care at the Saul and Joyce Brandman Breast Center. http://www.csmc.edu/14831.html.
Publication types
MeSH terms
Grants and funding
- R01 CA088370/CA/NCI NIH HHS/United States
- N01 PC035139/PC/NCI NIH HHS/United States
- N01-PC-35139/PC/NCI NIH HHS/United States
- P01 CA163233/CA/NCI NIH HHS/United States
- K05 CA111340/CA/NCI NIH HHS/United States
- N01 PC035139/CA/NCI NIH HHS/United States
- U58 DP000807/DP/NCCDPHP CDC HHS/United States
- N01 PC054404/CA/NCI NIH HHS/United States
- N01 PC035145/CA/NCI NIH HHS/United States
- N01-PC-54404/PC/NCI NIH HHS/United States
- K05CA111340/CA/NCI NIH HHS/United States
- N01-PC-35145/PC/NCI NIH HHS/United States
- R01 CA109696/CA/NCI NIH HHS/United States
- 1U58DP00807-01/DP/NCCDPHP CDC HHS/United States
